The success of trastuzumab in HER2+ breast cancer underscores the potential of targeting tyrosine kinases yet, in spite of this promising start, monotherapy with tyrosine kinase inhibitors (TKIs) has had limited success in the clinic. This evidence concerns the gene ERBB2 and breast carcinoma.